Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

GLP-1 receptor agonists and emerging inflammatory bowel disease

Impact of glucagon-like peptide-1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes.

Diabetes, obesity & metabolism

Citation & Authors

Diabetes Obes Metab. 2025;27(11):6403-6415.

Fu-Shun Yen; Shiow-Ing Wang; Yao-Min Hung; Chih-Cheng Hsu; Chii-Min Hwu; James C-C Wei

ABSTRACT · RESEARCH SUMMARY

Research summary

The TriNetX study used basal insulin, DPP-4 inhibitors, and SGLT2 inhibitors as active comparators. GLP-1 receptor agonists were associated with lower risks of incident IBD than the first two comparators (HRs 0.725 and 0.814), and with lower hospitalization risks in all three comparisons. The abstract did not report a significant reduction in IBD risk versus SGLT2 inhibitors; the findings should not be treated as identical across all comparisons.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗